JP7481342B2 - 多量体ｔ細胞調節ポリペプチド及びその使用方法 - Google Patents

多量体ｔ細胞調節ポリペプチド及びその使用方法 Download PDF

Info

Publication number
JP7481342B2
JP7481342B2 JP2021531836A JP2021531836A JP7481342B2 JP 7481342 B2 JP7481342 B2 JP 7481342B2 JP 2021531836 A JP2021531836 A JP 2021531836A JP 2021531836 A JP2021531836 A JP 2021531836A JP 7481342 B2 JP7481342 B2 JP 7481342B2
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
hla
acid sequence
examples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021531836A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020132138A5 (https=
JP2022515331A (ja
JP2022515331A5 (https=
Inventor
ザ サード ロナルド ディー． セイデル
ロドルフォ ジェイ． チャパーロ
Original Assignee
キュー バイオファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュー バイオファーマ， インコーポレイテッド filed Critical キュー バイオファーマ， インコーポレイテッド
Publication of JP2022515331A publication Critical patent/JP2022515331A/ja
Publication of JPWO2020132138A5 publication Critical patent/JPWO2020132138A5/ja
Publication of JP2022515331A5 publication Critical patent/JP2022515331A5/ja
Priority to JP2024070994A priority Critical patent/JP2024105344A/ja
Application granted granted Critical
Publication of JP7481342B2 publication Critical patent/JP7481342B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001181—Alpha-feto protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
JP2021531836A 2018-12-19 2019-12-18 多量体ｔ細胞調節ポリペプチド及びその使用方法 Active JP7481342B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024070994A JP2024105344A (ja) 2018-12-19 2024-04-25 多量体ｔ細胞調節ポリペプチド及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862782205P 2018-12-19 2018-12-19
US62/782,205 2018-12-19
US201962814707P 2019-03-06 2019-03-06
US62/814,707 2019-03-06
PCT/US2019/067280 WO2020132138A1 (en) 2018-12-19 2019-12-18 Multimeric t-cell modulatory polypeptides and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024070994A Division JP2024105344A (ja) 2018-12-19 2024-04-25 多量体ｔ細胞調節ポリペプチド及びその使用方法

Publications (4)

Publication Number Publication Date
JP2022515331A JP2022515331A (ja) 2022-02-18
JPWO2020132138A5 JPWO2020132138A5 (https=) 2022-12-26
JP2022515331A5 JP2022515331A5 (https=) 2022-12-26
JP7481342B2 true JP7481342B2 (ja) 2024-05-10

Family

ID=71100346

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531836A Active JP7481342B2 (ja) 2018-12-19 2019-12-18 多量体ｔ細胞調節ポリペプチド及びその使用方法
JP2024070994A Pending JP2024105344A (ja) 2018-12-19 2024-04-25 多量体ｔ細胞調節ポリペプチド及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024070994A Pending JP2024105344A (ja) 2018-12-19 2024-04-25 多量体ｔ細胞調節ポリペプチド及びその使用方法

Country Status (12)

Country Link
US (2) US20220389079A1 (https=)
EP (1) EP3897746A4 (https=)
JP (2) JP7481342B2 (https=)
KR (1) KR20210104700A (https=)
CN (1) CN113286621A (https=)
AU (1) AU2019401183A1 (https=)
BR (1) BR112021011838A2 (https=)
CA (1) CA3113096A1 (https=)
IL (1) IL282250A (https=)
MX (1) MX2021007479A (https=)
TW (1) TWI856048B (https=)
WO (1) WO2020132138A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024105344A (ja) * 2018-12-19 2024-08-06 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節ポリペプチド及びその使用方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116970059A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2022056015A1 (en) * 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides and methods of use thereof
EP4211149A4 (en) * 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
WO2024072958A1 (en) * 2022-09-30 2024-04-04 The Children's Hospital Of Philadelphia Systems, formulations and methods for generating universal peptide/mhc complexes with engineered disulfide connecting the heavy and light chains

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519491A (ja) 2014-06-18 2017-07-20 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド ｓｙｎＴａｃポリペプチド及びその使用
JP2017530102A (ja) 2014-08-29 2017-10-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 腫瘍を標的としたｉｌ−２バリアント免疫サイトカインとヒトｐｄ−ｌ１に対する抗体との併用療法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3322715B1 (en) * 2015-07-14 2023-10-18 BioNTech SE Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
CA3019005A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN116970059A (zh) * 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
AU2019401183A1 (en) * 2018-12-19 2021-08-12 Cue Biopharma, Inc. Multimeric T-cell modulatory polypeptides and methods of use thereof
CN118852456A (zh) * 2019-05-29 2024-10-29 Cue生物制药股份有限公司 多聚体t细胞调节多肽及其使用方法
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
WO2021081239A1 (en) * 2019-10-23 2021-04-29 Cue Biopharma, Inc. T-cell modulatory chimeric molecules and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519491A (ja) 2014-06-18 2017-07-20 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド ｓｙｎＴａｃポリペプチド及びその使用
JP2017530102A (ja) 2014-08-29 2017-10-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 腫瘍を標的としたｉｌ−２バリアント免疫サイトカインとヒトｐｄ−ｌ１に対する抗体との併用療法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024105344A (ja) * 2018-12-19 2024-08-06 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節ポリペプチド及びその使用方法

Also Published As

Publication number Publication date
TWI856048B (zh) 2024-09-21
AU2019401183A1 (en) 2021-08-12
US20250092113A1 (en) 2025-03-20
JP2022515331A (ja) 2022-02-18
TW202031680A (zh) 2020-09-01
MX2021007479A (es) 2021-09-23
US20220389079A1 (en) 2022-12-08
IL282250A (en) 2021-05-31
BR112021011838A2 (pt) 2021-08-31
JP2024105344A (ja) 2024-08-06
CA3113096A1 (en) 2020-06-25
EP3897746A4 (en) 2022-10-26
KR20210104700A (ko) 2021-08-25
EP3897746A1 (en) 2021-10-27
WO2020132138A1 (en) 2020-06-25
CN113286621A (zh) 2021-08-20

Similar Documents

Publication Publication Date Title
JP7481342B2 (ja) 多量体ｔ細胞調節ポリペプチド及びその使用方法
US11702461B2 (en) T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides
AU2018328280B2 (en) Multimeric T-cell modulatory polypeptides and methods of use thereof
JP7549579B2 (ja) 多量体ｔ細胞調節ポリペプチド及びその使用方法
US20240368245A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
US20240376177A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
US20230241192A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
EA049721B1 (ru) Модулирующие т-клетки мультимерные полипептиды и способы их применения
HK40060108A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221215

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240328

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240425

R150 Certificate of patent or registration of utility model

Ref document number: 7481342

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150